- Home
- TCRX vs LARK Comparison
TCRX vs LARK Comparison
Compare TCRX & LARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- LARK
- Stock Information
- Founded
- TCRX 2018
- LARK 1885
- Country
- TCRX United States
- LARK United States
- Employees
- TCRX N/A
- LARK N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- LARK Major Banks
- Sector
- TCRX Health Care
- LARK Finance
- Exchange
- TCRX Nasdaq
- LARK Nasdaq
- Market Cap
- TCRX 115.8M
- LARK 136.3M
- IPO Year
- TCRX 2021
- LARK N/A
- Fundamental
- Price
- TCRX $2.17
- LARK $24.11
- Analyst Decision
- TCRX Strong Buy
- LARK
- Analyst Count
- TCRX 5
- LARK 0
- Target Price
- TCRX $11.40
- LARK N/A
- AVG Volume (30 Days)
- TCRX 382.5K
- LARK 9.4K
- Earning Date
- TCRX 03-05-2025
- LARK 02-04-2025
- Dividend Yield
- TCRX N/A
- LARK 3.48%
- EPS Growth
- TCRX N/A
- LARK 6.33
- EPS
- TCRX N/A
- LARK 2.26
- Revenue
- TCRX $9,362,000.00
- LARK $58,168,000.00
- Revenue This Year
- TCRX N/A
- LARK N/A
- Revenue Next Year
- TCRX $5.14
- LARK N/A
- P/E Ratio
- TCRX N/A
- LARK $10.68
- Revenue Growth
- TCRX N/A
- LARK 3.55
- 52 Week Low
- TCRX $1.99
- LARK $17.05
- 52 Week High
- TCRX $9.69
- LARK $26.75
- Technical
- Relative Strength Index (RSI)
- TCRX 37.12
- LARK 46.44
- Support Level
- TCRX $2.02
- LARK $24.95
- Resistance Level
- TCRX $2.17
- LARK $26.13
- Average True Range (ATR)
- TCRX 0.16
- LARK 1.02
- MACD
- TCRX 0.02
- LARK -0.02
- Stochastic Oscillator
- TCRX 26.47
- LARK 30.89
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About LARK Landmark Bancorp Inc.
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The bank is principally engaged in the business of attracting deposits from the general public and using such deposits, together with borrowings and other funds, to originate one-to-four-family residential real estate, construction and land, commercial real estate, commercial, agriculture, municipal and consumer loans. In addition, it also invests in certain investment and mortgage related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.